Detalles de la búsqueda
1.
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Dig Dis Sci
; 68(2): 665-675, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976597
2.
Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C.
J Formos Med Assoc
; 122(2): 157-163, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36155707
3.
Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction.
Int J Clin Pract
; 75(4): e13945, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33338308
4.
Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment.
J Formos Med Assoc
; 120(1 Pt 3): 621-628, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32718890
5.
The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Invest New Drugs
; 38(1): 202-210, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31701431
6.
Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience.
J Viral Hepat
; 26(12): 1404-1412, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31433885
7.
Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
BMC Cancer
; 19(1): 1169, 2019 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31791275
8.
Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
J Formos Med Assoc
; 118(1 Pt 3): 504-513, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30527565
9.
The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Liver Int
; 38(6): 1064-1073, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29164767
10.
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
J Gastroenterol Hepatol
; 33(10): 1766-1772, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29514418
11.
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
J Formos Med Assoc
; 117(11): 1011-1018, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29254684
12.
Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease.
J Formos Med Assoc
; 117(4): 268-275, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28947134
13.
Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
J Formos Med Assoc
; 117(9): 833-840, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29089161
14.
The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.
J Formos Med Assoc
; 116(11): 852-861, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28888355
15.
Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
J Antimicrob Chemother
; 71(7): 1943-7, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27073265
16.
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
J Gastroenterol Hepatol
; 31(7): 1307-14, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26758501
17.
Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.
Antimicrob Agents Chemother
; 59(6): 3168-73, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25779569
18.
A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Clin Gastroenterol Hepatol
; 13(5): 1017-24, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25460552
19.
The validation of the 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area.
J Gastroenterol Hepatol
; 30(2): 345-51, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092265
20.
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.
Arch Virol
; 159(1): 29-37, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23857507